Adjuvant Immunotherapy Combinations on Horizon for Melanoma

15:36 EST 7 Nov 2019 | OncLive

Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.

Original Article: Adjuvant Immunotherapy Combinations on Horizon for Melanoma


More From BioPortfolio on "Adjuvant Immunotherapy Combinations on Horizon for Melanoma"

Quick Search

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...